ERK Cancer Research Results

ERK, ERK signaling: Click to Expand ⟱
Source:
Type:
MAPK3 (ERK1)
ERK proteins are kinases that activate other proteins by adding a phosphate group. An overactivation of these proteins causes the cell cycle to stop.
The extracellular signal-regulated kinase (ERK) signaling pathway is a crucial component of the mitogen-activated protein kinase (MAPK) signaling cascade, which plays a significant role in regulating various cellular processes, including proliferation, differentiation, and survival. high levels of phosphorylated ERK (p-ERK) in tumor samples may indicate active ERK signaling and could correlate with aggressive tumor behavior

EEk singaling is frequently activated and is often associated with aggressive tumor behavior, treatment resistance, and poor outcomes.
NA, Not Available: Click to Expand ⟱
none (reserved)
Scientific Papers found: Click to Expand⟱
309- AgNPs,    Interference of silver, gold, and iron oxide nanoparticles on epidermal growth factor signal transduction in epithelial cells
- in-vitro, NA, A431
ROS↑, Akt↓, p‑ERK↓,
1253- aLinA,    The Antitumor Effects of α-Linolenic Acid
- Review, NA, NA
PPARγ↑, COX2↓, E6↓, E7↓, P53↑, p‑ERK↓, p38↓, lipid-P↑, ROS⇅, MPT↑, MMP↓, Cyt‑c↑, Casp↑, iNOS↓, NO↓, Casp3↑, Bcl-2↓, Hif1a↓, FASN↓, CRP↓, IL6↓, IL1β↓, IFN-γ↓, TNF-α↓, Twist↓, VEGF↓, MMP2↓, MMP9↓,
1545- Api,    The Potential Role of Apigenin in Cancer Prevention and Treatment
- Review, NA, NA
TNF-α↓, IL6↓, IL1α↓, P53↑, Bcl-xL↓, Bcl-2↓, BAX↑, Hif1a↓, VEGF↓, TumCCA↑, DNAdam↑, Apoptosis↑, CycB/CCNB1↓, cycA1/CCNA1↓, CDK1↓, PI3K↓, Akt↓, mTOR↓, IKKα↓, ERK↓, p‑Akt↓, p‑P70S6K↓, p‑S6↓, p‑ERK↓, p‑P90RSK↑, STAT3↓, MMP2↓, MMP9↓, TumCP↓, TumCMig↓, TumCI↓, Wnt/(β-catenin)↓,
3392- ART/DHA,    Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways
- in-vitro, Nor, Hep3B - in-vivo, NA, NA
*Inflam↓, *NF-kB↓, *ROS↓, *p‑p38↓, *p‑ERK↓,
573- ART/DHA,    Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model
- vitro+vivo, NA, NA
p‑p38↓, p‑ERK↓, p‑CREB↓, p‑Chk2↓, p‑STAT5↓, p‑RSK↓, SOCS1↑, Apoptosis↑, Casp3↑,
556- ART/DHA,    Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing
- Review, NA, NA
IL6↓, IL1↓, TNF-α↓, TGF-β↓, NF-kB↓, MIP2↓, PGE2↓, NO↓, Hif1a↓, KDR/FLK-1↓, VEGF↓, MMP2↓, TIMP2↑, ITGB1↑, NCAM↑, p‑ATM↑, p‑ATR↑, p‑CHK1↑, p‑Chk2↑, Wnt/(β-catenin)↓, PI3K↓, Akt↓, ERK↓, cMyc↓, mTOR↓, survivin↓, cMET↓, EGFR↓, cycD1/CCND1↓, cycE1↓, CDK4/6↓, p16↑, p27↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, oncosis↑, TumCCA↑, ROS↑, DNAdam↑, RAD51↓, HR↓,
874- B-Gluc,    Potential promising anticancer applications of β-glucans: a review
- Review, NA, NA
AntiCan↑, TumCG↓, BAX↑, Bcl-2↓, IFN-γ↑, PI3K/Akt↑, MAPK↑, NFAT↑, NF-kB↑, ROS↑, NK cell↑, TumCCA↑, ERK↓, Telomerase↓,
2021- BBR,    Berberine: An Important Emphasis on Its Anticancer Effects through Modulation of Various Cell Signaling Pathways
- Review, NA, NA
*antiOx?, *Inflam↓, Apoptosis↑, TumCCA↑, BAX↑, eff↑, VEGF↓, PI3K↓, Akt↓, mTOR↓, Telomerase↓, β-catenin/ZEB1↓, Wnt↓, EGFR↓, AP-1↓, NF-kB↓, COX2↑, NRF2↓, RadioS↑, STAT3↓, ERK↓, AR↓, ROS↑, eff↑, selectivity↑, selectivity↑, BioAv↓, DNMT1↓, cMyc↓,
1299- BBR,    Effects of Berberine and Its Derivatives on Cancer: A Systems Pharmacology Review
- Review, NA, NA
TumCCA↑, TP53↑, COX2↓, Bax:Bcl2↑, ROS↑, VEGFR2↓, Akt↓, ERK↓, MMP2↓, MMP9↓, IL8↑, P21↑, p27↑, E-cadherin↓, Fibronectin↓, cMyc↓,
5683- BML,    Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway
- in-vitro, NA, NA
COX2↓, MAPK↓, NF-kB↓, TumMeta↓, P53↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, MAPK↓, ERK↓, Akt↓, TumVol↓,
726- Bor,    Redox Mechanisms Underlying the Cytostatic Effects of Boric Acid on Cancer Cells—An Issue Still Open
- Review, NA, NA
NAD↝, SAM-e↝, PSA↓, IGF-1↓, Cyc↓, P21↓, p‑MEK↓, p‑ERK↓, ROS↑, SOD↓, Catalase↓, MDA↑, GSH↓, IL1↓, IL6↓, TNF-α↓, BRAF↝, MAPK↝, PTEN↝, PI3K/Akt↝, eIF2α↑, ATF4↑, ATF6↑, NRF2↑, BAX↑, BID↑, Casp3↑, Casp9↑, Bcl-2↓, Bcl-xL↓,
1587- Citrate,    ATP citrate lyase: A central metabolic enzyme in cancer
- Review, NA, NA
ACLY↓, other↓, PFK1↓, ATP↓, PFK2↓, Mcl-1↓, Casp3↑, Casp2↑, Casp9↑, IGF-1R↓, PI3K↓, Akt↓, p‑Akt↓, p‑ERK↓, PTEN↑, Snail↓, E-cadherin↑, ChemoSen↑,
4764- CoQ10,  VitE,    Auxiliary effect of trolox on coenzyme Q10 restricts angiogenesis and proliferation of retinoblastoma cells via the ERK/Akt pathway
- in-vitro, RPE, Y79 - in-vitro, Nor, ARPE-19 - in-vivo, NA, NA
tumCV↓, Apoptosis↑, ROS↑, MMP↓, TumCCA↑, VEGF↓, ERK↓, Akt↓, ChemoSen↑, chemoP↑, toxicity↓, angioG↓,
670- EGCG,    Epigallocatechin-3-gallate and its nanoformulation in cervical cancer therapy: the role of genes, MicroRNA and DNA methylation patterns
- Review, NA, NA
TumCCA↑, P53↑, ERK↓, EGFR↓, p‑ERK↑, VEGF↓, Hif1a↓, miR-203↓, miR-210↑,
692- EGCG,    EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement
- Review, NA, NA
ROS↑, Apoptosis↑, DNAdam↑, CTR1↑, JWA↑, β-catenin/ZEB1↓, P53↑, Vim↓, VEGF↓, p‑Akt↓, Hif1a↓, COX2↓, ERK↓, NF-kB↓, Akt↓, Bcl-xL↓, miR-210↓,
691- EGCG,    Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer
- Review, NA, NA
Apoptosis↑, necrosis↑, TumAuto↑, ERK↓, p38↓, NF-kB↓, VEGF↓,
680- EGCG,    Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea
- Review, NA, NA
NF-kB↓, STAT3↓, PI3K↓, HGF/c-Met↓, Akt↓, ERK↓, MAPK↓, AR↓, Casp↑, Ki-67↓, PARP↑, Bcl-2↓, BAX↑, PCNA↓, p27↑, P21↑,
682- EGCG,    Suppressive Effects of EGCG on Cervical Cancer
- Review, NA, NA
E7↓, E6↓, PI3K/Akt↓, P53↑, p27↑, P21↑, CDK2↓, mTOR↓, HIF-1↓, IGF-1↓, EGFR↓, ERK↓, VEGF↓,
1155- F,    The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations
- Review, NA, NA
*toxicity↓, Casp3↑, Casp7↑, Casp8↑, Casp9↑, VEGF↓, angioG↓, PI3K↓, Akt↓, PARP↑, Bak↑, BID↑, Fas↑, Mcl-1↓, survivin↓, XIAP↓, ERK↓, EMT↓, EM↑, IM↓, Snail↓, Slug↓, Twist↓,
805- GAR,  Cisplatin,  PacT,    Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells
- Review, NA, NA
ERK↓, PI3K/Akt↓, Wnt/(β-catenin)↓, STAT3↓, NF-kB↓, ChemoSen↑, COX2↓, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, VEGF↓, TGF-β↓, HATs↓, E-cadherin↑, Vim↓, Zeb1↓, ZEB2↓, Let-7↑, MMP9↓, TumCCA↑, ROS↑, MMP↓, IL6↓, NOTCH1↓,
845- Gra,    A Review on Annona muricata and Its Anticancer Activity
- Review, NA, NA
GlucoseCon↓, ATP↓, HIF-1↓, GLUT1↓, GLUT4↓, HK2↓, LDHA↓, ERK↓, Akt↓, Apoptosis↑, NF-kB↓, ROS↑, Bax:Bcl2↑, MMP↓, Casp3↑, Casp9↑, p‑JNK↓,
1153- HNK,    Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor
- in-vitro, GBM, U251 - in-vitro, GBM, U87MG - in-vivo, NA, NA
tumCV↓, Apoptosis↑, TumCMig↓, TumCI↓, Bcl-2↓, EGFR↓, CD133↓, Nestin↓, Akt↓, ERK↓, Casp3↑, p‑STAT3↓, TumCG↓,
1141- Myr,    Myricetin: targeting signaling networks in cancer and its implication in chemotherapy
- Review, NA, NA
*PI3K↑, *Akt↑, p‑Akt↓, SIRT3↑, p‑ERK↓, p38↓, VEGF↓, MEK↓, MKK4↓, MMP9↓, Raf↓, F-actin↓, MMP2↓, COX2↓, BMP2↓, cycD1/CCND1↓, Bax:Bcl2↑, EMT↓, EGFR↓, TumAuto↑,
1799- NarG,    Naringenin as potent anticancer phytocompound in breast carcinoma: from mechanistic approach to nanoformulations based therapeutics
- Review, NA, NA
TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,
1811- Oxy,    Hyperbaric oxygen therapy and cancer—a review
- Review, NA, NA
toxicity∅, AntiTum↑, MAPK↑, ERK↓, ChemoSen↑, ChemoSen↑, RadioS↑,
3252- PBG,    Propolis Extract and Its Bioactive Compounds—From Traditional to Modern Extraction Technologies
- Review, NA, NA
*Inflam↓, *TNF-α↓, *NF-kB↓, *MAPK↓, *ERK↓, *antiOx↑, *NRF2↑, *cardioP↑, *Glycolysis↑, *Ca+2↓, *HO-1↑, *NRF2↑, *neuroP↑,
2995- PL,    Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover
- in-vitro, Lung, H1975 - in-vitro, Lung, PC9 - in-vivo, NA, NA
Sp1/3/4↓, cMET↓, Apoptosis↑, Cyt‑c↑, p‑ERK↓, p‑Akt↓, TumCG↓,
3350- QC,    Quercetin and the mitochondria: A mechanistic view
- Review, NA, NA
*antiOx↑, *Inflam↓, *NRF2↑, ROS⇅, *NRF2↑, *HO-1↑, *PPARα↑, *PGC-1α↑, *SIRT1↑, *ATP↑, ATP↓, ERK↓, cl‑PARP↑, Casp9↑, Casp8↑, BAX↑, MMP↓, Cyt‑c↑, Casp3↑, HSP27↓, HSP72↓, RAS↓, Raf↓,
3331- SIL,    The clinical anti-inflammatory effects and underlying mechanisms of silymarin
- Review, NA, NA
*Inflam↓, *NF-kB↓, *NLRP3↓, *COX2↓, *iNOS↓, *neuroP↑, *p‑ERK↓, *p38↓, *MAPK↓, *EGFR↓, *ROS↓, *lipid-P?, *5LO↓,
3304- SIL,    Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells
- in-vitro, GC, AGS - in-vivo, NA, NA
BAX↑, p‑JNK↑, p‑p38↑, cl‑PARP↑, Bcl-2↓, p‑ERK↓, TumVol↓, Apoptosis↑, tumCV↓,
3305- SIL,    Silymarin inhibits proliferation of human breast cancer cells via regulation of the MAPK signaling pathway and induction of apoptosis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vivo, NA, NA
TumCP↓, tumCV↓, BAX↑, cl‑PARP↑, Casp9↑, p‑JNK↑, Bcl-2↓, p‑p38↓, p‑ERK↓, *toxicity∅, Dose↝, *hepatoP↑, Inflam↓, AntiCan↑,
3295- SIL,    Hepatoprotective effect of silymarin
- Review, NA, NA
*hepatoP↑, *ROS↓, *GSH↑, *BioAv↝, ERK↓, NF-kB↓, STAT3↓, COX2↓, Inflam↓, IronCh↑, lipid-P↓, ALAT↓, AST↓, TNF-α↓, *α-SMA↓, *SOD↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
978- SIL,    A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment
- Review, NA, NA
PI3K↓, Akt↓, NF-kB↓, Wnt/(β-catenin)↓, MAPK↓, TumCP↓, TumCCA↑, Apoptosis↑, p‑EGFR↓, JAK2↓, STAT5↓, cycD1/CCND1↓, hTERT/TERT↓, AP-1↓, MMP9↓, miR-21↓, miR-155↓, Casp9↑, BID↑, ERK↓, Akt2↓, DNMT1↓, P53↑, survivin↓, Casp3↑, ROS↑,

Showing Research Papers: 1 to 34 of 34

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 34

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↓, 1,   Ferroptosis↑, 1,   GSH↓, 2,   lipid-P↓, 1,   lipid-P↑, 1,   MDA↑, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 14,   ROS⇅, 2,   SAM-e↝, 1,   SIRT3↑, 1,   SOD↓, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 4,   EGF↓, 1,   MEK↓, 1,   p‑MEK↓, 1,   MKK4↓, 1,   MMP↓, 6,   MPT↑, 1,   Raf↓, 2,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACLY↓, 1,   ALAT↓, 1,   cMyc↓, 3,   p‑CREB↓, 1,   FASN↓, 1,   GlucoseCon↓, 1,   HK2↓, 1,   LDHA↓, 1,   NAD↝, 1,   PFK1↓, 1,   PFK2↓, 1,   PI3K/Akt↓, 2,   PI3K/Akt↑, 1,   PI3K/Akt↝, 1,   PPARγ↑, 1,   p‑S6↓, 1,   SIRT1↓, 1,   SREBP1↓, 1,  

Cell Death ⓘ

Akt↓, 15,   p‑Akt↓, 5,   Apoptosis↑, 12,   Bak↑, 2,   BAX↑, 11,   Bax:Bcl2↑, 3,   Bcl-2↓, 10,   Bcl-xL↓, 3,   BID↑, 3,   BMP2↓, 1,   Casp↑, 3,   Casp2↑, 1,   Casp3↑, 12,   Casp7↑, 1,   Casp8↑, 3,   Casp9↑, 9,   p‑Chk2↓, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 4,   Fas↑, 1,   Ferroptosis↑, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 1,   iNOS↓, 1,   p‑JNK↓, 1,   p‑JNK↑, 2,   JWA↑, 1,   MAPK↓, 5,   MAPK↑, 2,   MAPK↝, 1,   Mcl-1↓, 2,   necrosis↑, 1,   oncosis↑, 1,   p27↑, 5,   p38↓, 3,   p‑p38↓, 2,   p‑p38↑, 1,   p‑RSK↓, 1,   survivin↓, 3,   Telomerase↓, 3,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

HATs↓, 1,   HATs↑, 1,   miR-21↓, 1,   other↓, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

ATF6↑, 1,   eIF2α↑, 1,   HSP27↓, 1,   HSP72↓, 1,  

Autophagy & Lysosomes ⓘ

TumAuto↑, 3,  

DNA Damage & Repair ⓘ

p‑ATM↑, 1,   p‑ATR↑, 1,   p‑CHK1↑, 1,   DNAdam↑, 3,   DNMT1↓, 2,   HR↓, 1,   p16↑, 1,   P53↑, 7,   PARP↑, 2,   cl‑PARP↑, 3,   PCNA↓, 1,   RAD51↓, 1,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 1,   Cyc↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 3,   cycE1↓, 1,   P21↓, 1,   P21↑, 4,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State ⓘ

BRAF↝, 1,   CD133↓, 1,   CD44↓, 1,   cMET↓, 2,   EMT↓, 4,   ERK↓, 22,   p‑ERK↓, 10,   p‑ERK↑, 1,   HDAC↓, 1,   IGF-1↓, 2,   IGF-1R↓, 1,   IGFBP3↑, 1,   Let-7↑, 1,   mTOR↓, 5,   Nestin↓, 1,   NOTCH↓, 1,   NOTCH1↓, 1,   p‑P70S6K↓, 1,   p‑P90RSK↑, 1,   PI3K↓, 8,   PTEN↑, 1,   PTEN↝, 1,   RAS↓, 1,   STAT3↓, 6,   p‑STAT3↓, 1,   STAT5↓, 1,   p‑STAT5↓, 1,   TumCG↓, 4,   Wnt↓, 2,   Wnt/(β-catenin)↓, 4,  

Migration ⓘ

Akt2↓, 1,   AP-1↓, 2,   CA↓, 1,   Ca+2↑, 1,   CDK4/6↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 3,   EM↑, 1,   F-actin↓, 1,   FAK↓, 1,   Fibronectin↓, 1,   ITGB1↑, 1,   Ki-67↓, 1,   miR-155↓, 1,   miR-203↓, 1,   miR-203↑, 1,   MMP2↓, 7,   MMP9↓, 8,   NCAM↑, 1,   NFAT↑, 1,   PDGF↓, 1,   Slug↓, 1,   Snail↓, 2,   TGF-β↓, 3,   TIMP2↑, 1,   TumCI↓, 2,   TumCMig↓, 3,   TumCP↓, 3,   TumMeta↓, 1,   Twist↓, 2,   uPA↓, 1,   Vim↓, 3,   Zeb1↓, 2,   ZEB2↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   ATF4↑, 1,   EGFR↓, 7,   p‑EGFR↓, 1,   HIF-1↓, 2,   Hif1a↓, 6,   KDR/FLK-1↓, 1,   miR-210↓, 1,   miR-210↑, 1,   NO↓, 2,   VEGF↓, 15,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

CTR1↑, 1,   GLUT1↓, 1,   GLUT4↓, 1,   NHE1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 8,   COX2↑, 1,   CRP↓, 1,   IFN-γ↓, 1,   IFN-γ↑, 1,   IKKα↓, 1,   IL1↓, 3,   IL1α↓, 1,   IL1β↓, 1,   IL6↓, 5,   IL8↑, 1,   Inflam↓, 2,   JAK2↓, 1,   MIP2↓, 1,   NF-kB↓, 12,   NF-kB↑, 1,   NK cell↑, 1,   PD-L1↓, 1,   PGE2↓, 2,   PSA↓, 2,   SOCS1↑, 1,   TNF-α↓, 6,  

Cellular Microenvironment ⓘ

IM↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 3,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 1,   ChemoSen↑, 6,   Dose↝, 2,   eff↑, 2,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   Half-Life∅, 1,   RadioS↑, 2,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AR↓, 3,   AST↓, 1,   BRAF↝, 1,   CRP↓, 1,   E6↓, 2,   E7↓, 2,   EGFR↓, 7,   p‑EGFR↓, 1,   hTERT/TERT↓, 1,   IL6↓, 5,   Ki-67↓, 1,   PD-L1↓, 1,   PSA↓, 2,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 3,   AntiTum↑, 1,   cardioP↑, 1,   chemoP↑, 2,   hepatoP↑, 1,   OS↑, 1,   toxicity↓, 1,   toxicity↝, 1,   toxicity∅, 2,   TumVol↓, 2,  
Total Targets: 259

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx?, 1,   antiOx↑, 3,   GSH↑, 1,   HO-1↑, 2,   lipid-P?, 1,   NRF2↑, 4,   ROS↓, 3,   SOD↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

Glycolysis↑, 1,   PPARα↑, 1,   SIRT1↑, 2,  

Cell Death ⓘ

Akt↑, 1,   iNOS↓, 1,   MAPK↓, 2,   p38↓, 1,   p‑p38↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   p‑ERK↓, 2,   PI3K↑, 1,  

Migration ⓘ

5LO↓, 1,   Ca+2↓, 1,   TIMP1↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL8↓, 1,   Inflam↓, 6,   NF-kB↓, 3,   TNF-α↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,  

Clinical Biomarkers ⓘ

EGFR↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   hepatoP↑, 2,   neuroP↑, 2,   toxicity↓, 1,   toxicity∅, 1,  
Total Targets: 39

Scientific Paper Hit Count for: ERK, ERK signaling
6 Silymarin (Milk Thistle) silibinin
5 EGCG (Epigallocatechin Gallate)
3 Artemisinin
2 Berberine
1 Silver-NanoParticles
1 alpha Linolenic acid
1 Apigenin (mainly Parsley)
1 beta-glucans
1 Bromelain
1 Boron
1 Citric Acid
1 Coenzyme Q10
1 Vitamin E
1 Fucoidan
1 Garcinol
1 Cisplatin
1 Paclitaxel
1 Graviola
1 Honokiol
1 Myricetin
1 Naringin
1 Oxygen, Hyperbaric
1 Propolis -bee glue
1 Piperlongumine
1 Quercetin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:0  Cells:%  prod#:%  Target#:105  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page